tiprankstipranks
Scholar Rock Unveils Promising Cancer Trial Results at ASCO 2024
Company Announcements

Scholar Rock Unveils Promising Cancer Trial Results at ASCO 2024

Don't Miss Our Christmas Offers:

The latest update is out from Scholar Rock Holding (SRRK).

Scholar Rock Holding Corporation revealed promising results from its Phase 1 DRAGON trial of SRK-181 with pembrolizumab for advanced solid tumors at the ASCO 2024 Annual Meeting, showing the treatment’s good tolerance and encouraging responses in various cancers. Key findings included a correlation between CD8+ T-cell presence and improved response rates in renal cell carcinoma. The company plans to discuss the details in a conference call and suggests that CD8+ status and regulatory T-cell levels may be biomarkers for identifying patients most likely to benefit from the treatment.

Learn more about SRRK stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyScholar Rock price target raised to $45 from $36 at Truist
TheFlyScholar Rock price target raised to $50 from $40 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App